Adjustment of dosing of antimicrobial agents for bodyweight in adults

[1]  M. Falagas,et al.  Effect of body mass index on the outcome of infections: a systematic review , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[2]  D. Paterson,et al.  Antibiotic resistance—What’s dosing got to do with it? , 2008, Critical care medicine.

[3]  C. Apovian,et al.  Obesity prevalence from a European perspective: a systematic review , 2008, BMC public health.

[4]  Ronald G Hall,et al.  Multicenter evaluation of vancomycin dosing: emphasis on obesity. , 2008, The American journal of medicine.

[5]  Á. Soriano,et al.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  C. Raehl,et al.  2006 National Clinical Pharmacy Services Survey: Clinical Pharmacy Services, Collaborative Drug Management, Medication Errors, and Pharmacy Technology , 2008, Pharmacotherapy.

[7]  D. T. Bearden,et al.  Antimicrobial Dosing Considerations in Obese Adult Patients , 2007, Pharmacotherapy.

[8]  C. Peck,et al.  “Getting the Dose Right”: Facts, a Blueprint, and Encouragements , 2007, Clinical pharmacology and therapeutics.

[9]  J. Norenberg,et al.  Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin , 2007, Antimicrobial Agents and Chemotherapy.

[10]  M. Falagas,et al.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? , 2007, International journal of antimicrobial agents.

[11]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Falagas,et al.  Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. , 2006, The Journal of hospital infection.

[13]  M. Falagas,et al.  Obesity and infection. , 2006, The Lancet. Infectious diseases.

[14]  K. Flegal,et al.  Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.

[15]  J. J. Homan van der Heide,et al.  Obesity and renal hemodynamics. , 2006, Contributions to nephrology.

[16]  Imke H. Bartelink,et al.  Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations , 2006, Clinical pharmacokinetics.

[17]  Matthew E Falagas,et al.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  N. Byrne,et al.  A semi-mechanistic model for quantification of lean body weight , 2005 .

[19]  Stephen B. Duffull,et al.  Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.

[20]  C. Carpenter,et al.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[22]  B. Erstad.  Which weight for weight-based dosage regimens in obese patients? , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  U. Brinkmann,et al.  How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport , 2000, Clinical chemistry and laboratory medicine.

[24]  R. Blouin,et al.  Pharmacokinetic considerations in obesity. , 1999, Journal of pharmaceutical sciences.

[25]  P. Angus,et al.  Relationships among liver and kidney volumes, lean body mass and drug clearance. , 1998, British journal of clinical pharmacology.

[26]  L. Bauer,et al.  Vancomycin dosing in morbidly obese patients , 1998, European Journal of Clinical Pharmacology.

[27]  M. Cetron,et al.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. , 1995, The New England journal of medicine.

[28]  T. Pearson,et al.  Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology , 1995, British journal of haematology.

[29]  A. Traynor,et al.  Aminoglycoside dosing weight correction factors for patients of various body sizes , 1995, Antimicrobial agents and chemotherapy.

[30]  E. Vollaard,et al.  Colonization resistance , 1994, Antimicrobial Agents and Chemotherapy.

[31]  P. McNamara,et al.  Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. , 1984, British journal of clinical pharmacology.